Cancer cell membrane fused liposomal platinum(IV) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy.
J Mater Chem B
; 11(47): 11384-11393, 2023 12 06.
Article
em En
| MEDLINE
| ID: mdl-38014915
ABSTRACT
Esophageal squamous cell carcinoma (ESCC) remains a major health challenge, with cisplatin (CDDP) being the primary chemotherapy drug, albeit accompanied by resistance development over time. This study introduces a novel platinum drug delivery system, EMLipoPt(IV), tailored to enhance platinum uptake and diminish its inactivation, providing a solution to CDDP resistance in ESCC. By synthesizing a fusion of the ESCC cell membrane with liposomal Pt(IV) prodrugs, we integrated the tumor-targeting capacity of the ESCC membrane with the inactivation resistance of Pt(IV) prodrugs. In vivo and in vitro evaluations illustrated EMLipoPt(IV)'s robustness against inactivating agents, superior tumor-targeting capacity, and remarkable ability to suppress CDDP-resistant tumor progression. Importantly, the biosafety profile of EMLipoPt(IV) surpassed existing treatments, offering a prolonged survival rate in animal models. Collectively, this work not only presents a pioneering approach in ESCC chemotherapy but also provides a blueprint for combating drug resistance in other cancers, emphasizing the broader potential for tailored drug delivery systems.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Esofágicas
/
Pró-Fármacos
/
Carcinoma de Células Escamosas do Esôfago
Limite:
Animals
Idioma:
En
Revista:
J Mater Chem B
Ano de publicação:
2023
Tipo de documento:
Article